肿瘤细胞的异常糖代谢

doi:10.3760/cma.j.issn.1673-422X.2013.12.001

摘要/Abstract

摘要： 肿瘤细胞糖代谢异常与多种机制有关，如缺氧诱导因子（HIF）的参与可激活糖酵解相关酶类，有利于肿瘤细胞采取糖酵解方式获能；线粒体功能低下或数量减少可一定程度抑制葡萄糖氧化磷酸化途径；某些癌基因的激活及抑癌基因的失活也参与调节线粒体氧化呼吸链及糖酵解相关酶类，从而影响糖代谢过程；肿瘤细胞氧化磷酸化的相关酶类合成受到抑制等。此外，糖代谢异常对肿瘤细胞的生长、侵袭和转移具有重要作用。

关键词: 糖酵解, 线粒体, 肿瘤, 缺氧诱导因子

Abstract: The abnormal glucose metabolism of tumor cells is associated with a variety of mechanisms. Hypoxia inducible factor (HIF) is able to activate the glycolytic enzymes, which is conducive to getting energy through glycolysis. The dysfunction or the depletion in numbers of mitochondria can inhibit the oxidative phosphorylation pathway of glucose to some extent. The activation of oncogenes and the inactivation of tumor suppressor genes are also involved in the regulation of mitochondrial respiratory chain and glycolytic enzymes, thus affecting the process of glucose metabolism. Compared with normal cells, the synthesis of oxidative phosphorylation enzymes is inhibited in cancer cells. In addition, the abnormal glucose metabolism plays an important role in the growth, invasion and metastasis of tumor cells.

Key words: Glycolysis, Mitochondria, Neoplasms, Hypoxia inducible factor

孙洁, 孟祥军. 肿瘤细胞的异常糖代谢[J]. 国际肿瘤学杂志, 2013, 40(12): 883-885.

SUN Jie, MENG Xiang-Jun. Abnormal glycometabolism in tumor cells[J]. Journal of International Oncology, 2013, 40(12): 883-885.

参考文献

［1］ El Mjiyad N, CaroMaldonado A, RamirezPeinado S, et al. Sugarfree approaches to cancer cell killing. Oncogene, 2011, 30(3): 253-264. ［2］ Levine AJ, PuzioKuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 2010, 330(6009): 1340-1344. ［3］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144(5): 646-674. ［4］ Luo W, Zhong J, Chang R, et al. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxiainducible factor (HIF)1alpha but Not HIF2alpha. J Biol Chem, 2010, 285(6): 3651-3663. ［5］ Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol, 2011, 27: 441-464. ［6］ Koh MY, Lemos R Jr, Liu X, et al. The hypoxiaassociated factor switches cells from HIF1α to HIF2αdependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res, 2011, 71(11): 4015-4027. ［7］ Koppenol WH, Bounds PL, Dang CV. Otto Warburg′s contributions to current concepts of cancer metabolism. Nat Rev Cancer, 2011, 11(5): 325-337. ［8］ Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor′s dilemma?. Biochim Biophys Acta, 2011, 1807(6): 552-561. ［9］ Smolkova K, PlecitaHlavata L, Bellance N, et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol, 2011, 43(7): 950-968. ［10］ MorenoSanchez R, RodriguezEnriquez S, Saavedra E, et al. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells?. Bilfactors, 2009, 35(2): 209-225. ［11］ Dang CV. Links between metabolism and cancer. Genes Dev, 2012, 26(9): 877-890. ［12］ Gao P, Tchernyshyov I, Chang TC, et al. cMyc suppression of miR23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458(7239): 762-765. ［13］ Semenza GL. HIF1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev, 2010, 20(1): 51-56. ［14］ Green ML, Pisano MM, Prough RA, et al. Release of targeted p53 from the mitochondrion as an early signal during mitochondrial dysfunction. Cell Signal, 2013, 25(12): 2383-2390. ［15］ Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev, 2009, 23(5): 537-548. ［16］ Liu P, Cheng H, Santiago S, et al. Oncogenic PIK3CAdriven mammary tumors frequently recur via PI3K pathwaydependent and PI3K pathwayindependent mechanisms. Nat Med, 2011, 17(9): 1116-1120. ［17］ Ilic N, Utermark T, Widlund HR, et al. PI3Ktargeted therapy can be evaded by gene amplification along the MYCeukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA, 2011, 108(37): E699-708. ［18］ Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin, 2013, 45(1): 18-26. ［19］ Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin upregulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA, 2011, 108(10): 4129-4134. ［20］ Zha X, Wang F, Wang Y, et al. Lactate dehydrogenase B is critical for hyperactive mTORmediated tumorigenesis. Cancer Res, 2011, 71(1): 13-18. ［21］ Hirasawa T, Miyazawa M, Yasuda M, et al. Alterations of hypoxiainduced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. Int J Gynecol Cancer, 2013, 23(7): 1210-1218. ［22］ Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther, 2013, 137(3): 318-330. ［23］ Hardee ME, Dewhirst MW, Agarwal N, et al. Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr Mol Med, 2009, 9(4): 435-441. ［24］ Gammon L, Biddle A, Heywood HK, et al. Subsets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One, 2013, 8(4): e62493. ［25］ Icard P, Lincet H. The cancer tumor: a metabolic parasite?. Bull Cancer, 2013, 100(5): 427-433. ［26］ Chiu M, Ottaviani L, Bianchi MG, et al. Towards a metabolic therapy of cancer?. Acta Biomed, 2012, 83(3): 168-176.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.